Wiktoria Blaszczak - Search Results

Year	Number of Results
2017	1
2018	2
2019	1
2021	2
2022	3
2023	3
2024	1

1

Outlook of women in science: an interview with our authors.

Blaszczak W, Ahmed A, Leithner K, Schubert A, Leech M, Bonder C, Tsagakis I. Blaszczak W, et al. Mol Oncol. 2022 Mar;16(5):1047-1056. doi: 10.1002/1878-0261.13189. Epub 2022 Mar 1. Mol Oncol. 2022. PMID: 35122410 Free PMC article. Review.

2

What do cellular responses to acidity tell us about cancer?

Blaszczak W, Swietach P. Blaszczak W, et al. Cancer Metastasis Rev. 2021 Dec;40(4):1159-1176. doi: 10.1007/s10555-021-10005-3. Epub 2021 Nov 30. Cancer Metastasis Rev. 2021. PMID: 34850320 Free PMC article. Review.

3

Permeability and driving force: why is difficult to control glycolytic flux by blocking lactate transporters?

Blaszczak W, Swietach P. Blaszczak W, et al. Oncotarget. 2023 Jan 26;14:51-52. doi: 10.18632/oncotarget.28351. Oncotarget. 2023. PMID: 36702333 Free PMC article. No abstract available.

4

Acid-adapted cancer cells alkalinize their cytoplasm by degrading the acid-loading membrane transporter anion exchanger 2, SLC4A2.

Michl J, Monterisi S, White B, Blaszczak W, Hulikova A, Abdullayeva G, Bridges E, Yin Z, Bodmer WF, Swietach P. Michl J, et al. Among authors: blaszczak w. Cell Rep. 2023 Jun 27;42(6):112601. doi: 10.1016/j.celrep.2023.112601. Epub 2023 Jun 3. Cell Rep. 2023. PMID: 37270778 Free article.

5

Vitamin C as a Modulator of the Response to Cancer Therapy.

Blaszczak W, Barczak W, Masternak J, Kopczyński P, Zhitkovich A, Rubiś B. Blaszczak W, et al. Molecules. 2019 Jan 28;24(3):453. doi: 10.3390/molecules24030453. Molecules. 2019. PMID: 30695991 Free PMC article. Review.

6

Dynamic IL-6R/STAT3 signaling leads to heterogeneity of metabolic phenotype in pancreatic ductal adenocarcinoma cells.

Blaszczak W, White B, Monterisi S, Swietach P. Blaszczak W, et al. Cell Rep. 2024 Jan 23;43(1):113612. doi: 10.1016/j.celrep.2023.113612. Epub 2023 Dec 23. Cell Rep. 2024. PMID: 38141171 Free article.

7

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.

Blaszczak W, Barczak W, Wegner A, Golusinski W, Suchorska WM. Blaszczak W, et al. Med Oncol. 2017 Apr;34(4):60. doi: 10.1007/s12032-017-0918-1. Epub 2017 Mar 17. Med Oncol. 2017. PMID: 28315228 Free PMC article. Review.

8

Immune modulation underpins the anti-cancer activity of HDAC inhibitors.

Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, Zheng S, Kerr D, Samsonova A, La Thangue NB. Blaszczak W, et al. Mol Oncol. 2021 Dec;15(12):3280-3298. doi: 10.1002/1878-0261.12953. Epub 2021 May 1. Mol Oncol. 2021. PMID: 33773029 Free PMC article.

9

CRISPR-Cas9 screen identifies oxidative phosphorylation as essential for cancer cell survival at low extracellular pH.

Michl J, Wang Y, Monterisi S, Blaszczak W, Beveridge R, Bridges EM, Koth J, Bodmer WF, Swietach P. Michl J, et al. Among authors: blaszczak w. Cell Rep. 2022 Mar 8;38(10):110493. doi: 10.1016/j.celrep.2022.110493. Cell Rep. 2022. PMID: 35263578 Free PMC article.

10

Autoregulation of H⁺/lactate efflux prevents monocarboxylate transport (MCT) inhibitors from reducing glycolytic lactic acid production.

Blaszczak W, Williams H, Swietach P. Blaszczak W, et al. Br J Cancer. 2022 Oct;127(7):1365-1377. doi: 10.1038/s41416-022-01910-7. Epub 2022 Jul 15. Br J Cancer. 2022. PMID: 35840734 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year